Importantly, this combination also prolonged progression-free survival in cancer patients who had previously developed resistance to PD-1/PD-L1 therapy, suggesting that β-glucan can reverse immune escape by reprogramming innate and adaptive responses. The gene discussed is CD274; the disease is cancer.